Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a retrospective study by leading interventional radiologists and oncologists from Asklepios Hospital Barmbek in Hamburg, Germany. The study, titled “Survival Outcome After Percutaneous Hepatic Perfusion with High-Dose Melphalan for Liver-Dominant Metastatic Uve.

Business Wire • Dec 3, 2025

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath”) an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver, today announced that its Board of Directors has authorized a share repurchase program under which Delcath may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions. The repurchase program does not have an expiration date. “The share repurcha.

Business Wire • Nov 20, 2025

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion,” was published in the Journal of Vascular and Interv.

Business Wire • Nov 18, 2025

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to six individuals whose employment commenced in either September 2025 or October 2025. The grants resulted in the right to purchase 62,500 shares of the.

Business Wire • Nov 14, 2025

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021,” was published in the In.

Business Wire • Nov 13, 2025

Delcath Systems to Participate in Upcoming Investor Conferences

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: Craig-Hallum Alpha Select Conference on Tuesday, November 18, 2025, in New York, NY Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 20, 2025, in New York, NY About Delcath Systems.

Business Wire • Nov 6, 2025

Delcath: Temporary Headwinds Are No Cause For Concern

Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time.

Seeking Alpha • Nov 6, 2025

Delcath Systems, Inc. (DCTH) Q3 2025 Earnings Call Transcript

Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Marie Thibault - BTIG, LLC, Research Division John Newman - Canaccord Genuity Corp., Research Division Jake Soucheray Kesav Chandrasekhar Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Yale Jen Bill Maughan Presentation Operator ” David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer ” Gerard Michel CEO & Director ” Sandra Pennell Chief Financial Officer ” Vojislav Vukovic Chief Medical Officer ” Marie Thibault BTIG, LLC, Research Division ” BTIG, LLC, Research Division John Newman Canaccord Genuity Corp., Research Division ” Canaccord Genuity Corp., Research Division Jake Soucheray ” Craig-Hallum Capital Group LLC, Research Division Kesav Chandrasekhar ” Stephens Inc., Research Division Swayampakula Ramakanth H.C.

Seeking Alpha • Nov 4, 2025

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Total revenue of $20.6 million, compared with $11.2 million in the third quarter of 2024 HEPZATO KIT™ revenue of $19.3 million, compared to $10.0 million.

Business Wire • Nov 4, 2025

Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.03 per share a year ago.

Zacks Investment Research • Nov 4, 2025